Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022

New immune evasive variants of SARS‐CoV‐2 continue to emerge, potentially causing new waves of covid‐19 disease. Here, we evaluate levels of neutralizing antibodies against isolates of Omicron variants, including BQ.1.1 and XBB, in sera harvested 3–4 weeks after vaccination or breakthrough infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Vikse, Elisabeth Lea, Fossum, Even, Erdal, Magnhild Sekse, Hungnes, Olav, Bragstad, Karoline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236499/
https://www.ncbi.nlm.nih.gov/pubmed/37273461
http://dx.doi.org/10.1111/irv.13144
Descripción
Sumario:New immune evasive variants of SARS‐CoV‐2 continue to emerge, potentially causing new waves of covid‐19 disease. Here, we evaluate levels of neutralizing antibodies against isolates of Omicron variants, including BQ.1.1 and XBB, in sera harvested 3–4 weeks after vaccination or breakthrough infections. In addition, we evaluate neutralizing antibodies in 32 sera from October 2022, to evaluate immunity in Norwegian donors prior to the winter season. Most serum samples harvested in October 2022 had low levels of neutralizing antibodies against BQ.1.1 and especially XBB, explaining why these variants and their descendants have dominated in Norway during the 2022 and 2023 winter season.

Ejemplares similares